Previous 10 | Next 10 |
The following slide deck was published by Precigen, Inc. in conjunction with their 2022 Q2 earnings call. For further details see: Precigen, Inc. 2022 Q2 - Results - Earnings Call Presentation
Precigen press release ( NASDAQ: PGEN ): Q2 GAAP EPS of -$0.09 beats by $0.05 . Revenue of $2.91M (-23.8% Y/Y). "The transaction to sell Trans Ova Genetics, which is expected to close in Q3 2022, will provide Precigen with $170 million in cash up-front and up to a ...
Precigen Reports Second Quarter and First Half 2022 Financial Results PR Newswire – Enrollment complete in Phase 1 study of PRGN-3006 UltraCAR-T ® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; ...
Major earnings expected after the bell on Monday include: 3D Systems ( DDD ) Lemonade ( LMND ) Novavax ( NVAX ) Take-Two Interactive Software ( TTWO ) Upstart Holdings ( UPST ) For further details see: Notable earnings after Monday's close...
Precigen ( NASDAQ: PGEN ) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close. The consensus EPS Estimate is -$0.14 (-40.0% Y/Y) and the consensus Revenue Estimate is $22.54M (-32.9% Y/Y). Over the last 3 months, EPS estimates have se...
Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th PR Newswire GERMANTOWN, Md. , Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene an...
Gainers: Inspira Technologies Oxy ( IINN ) +98% . Cano Health CANO +18% . Veru VERU +16% . Amylyx Pharmaceuticals ( AMLX ) +13% . Equillium ( EQ ) +12% . Losers: Applied Molecular Transport AMTI -26% . HTG Molecular D...
Gainers: Alpha Tau Medical ( DRTS ) +42% . Precigen ( PGEN ) +20% . Amylyx Pharmaceuticals ( AMLX ) +18% . bluebird bio ( BLUE ) +13% . Talaris Therapeutics ( TALS ) +11% . Losers: Revelation Biosciences ( REVB ...
The shares of the development stage biotech Precigen ( NASDAQ: PGEN ) climbed in the pre-market Tuesday after the company announced an agreement to sell its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, to URUS. Per the terms, URUS, a holding company focused ...
Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics PR Newswire – Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out ...
News, Short Squeeze, Breakout and More Instantly...
2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...
2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...
Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints ...